Apolipoprotein A-V (ApoA-V)

Apolipoprotein A-V (ApoA-V) is a protein encoded by the APOA5 gene and is principally expressed in the liver[7]. It is a minor plasma apolipoprotein found in several lipoprotein fractions, including VLDL, HDL, and chylomicrons[7]. ApoA-V is a crucial determinant of plasma triglyceride levels and acts as a regulator of lipid metabolism. Its functional mechanisms include the activation of lipoprotein lipase for enhanced triglyceride catabolism, inhibition of VLDL particle assembly and hepatic secretion, and interaction with receptors important for remnant clearance[7]. Genetic studies have demonstrated that alterations of APOA5 expression strongly influence plasma triglyceride levels, thereby impacting the risk for cardiovascular diseases and metabolic syndrome[7]. Structurally, ApoA-V displays features typical of exchangeable apolipoproteins, including lipid-binding regions and a helix bundle domain[2][4][5]. It has unique physicochemical properties (very hydrophobic, distinct structural domains) and is found in extremely low concentrations in plasma compared to other apolipoproteins[4]. No approved drugs directly target ApoA-V, but its plasma level and genetic status serve as biomarkers for triglyceride-rich dyslipidemias and associated cardiovascular risk[7].

Other names

Apolipoprotein AVApoAVAPOA5 proteinApolipoprotein A5

Activation of lipoprotein lipase (enhancing triglyceride catabolism)[7]; Inhibition of hepatic VLDL particle assembly and secretion[7]; Facilitation of hepatic uptake of lipoprotein remnants by interacting with receptors of the LDL receptor gene family[7]; Modulation of HDL maturation[7]